Drugs Xagena
The FDA ( Food and Drug Administration ) has approved Crestor ( Rosuvastatin ) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol.
The submission package to the FDA was based largely on the results of a pivotal study called METEOR ( Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin ) which measured the effects of Rosuvastatin on plaque build-up in the arteries using carotid intima-media thickness ( CIMT ) and demonstrated a slowing of progression of atherosclerosis in people with early signs of the disease, elevated LDL cholesterol, and low cardiovascular risk, taking Rosuvastatin 40 mg.
Among participants in the Rosuvastatin group, the mean baseline LDL cholesterol level of 155 mg/dL declined to 78 mg/dL, a mean reduction of 49% ( P
